BUILD 3: Bosentan Use in Interstitial Lung Disease
Status and phase
Completed
Phase 3
Conditions
Idiopathic Pulmonary Fibrosis
Treatments
Drug: Bosentan
Drug: Placebo
Details and patient eligibility
About
BUILD 3 is a prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, event-driven, group sequential, phase III superiority study. The primary objective is to demonstrate that bosentan delays disease worsening or death in patients with Idiopathic Pulmonary Fibrosis.
Enrollment
616 patients
Sex
All
Ages
18+ years old
Volunteers
No Healthy Volunteers
Inclusion criteria
- Signed informed consent
- Male or female aged 18 years or older (females of child-bearing potential must have been surgically sterilized or use a reliable method of contraception.)
- Proven diagnosis of IPF according to American Thoracic Society / European Respiratory Society (ATS-ERS) statement, of <3 years, with surgical lung biopsy (SLB)
Exclusion criteria
- Interstitial lung disease due to conditions other than IPF.
- Presence of extensive honeycombing (HC) on baseline high-resolution computed tomography (HRCT) scan.
- Severe concomitant illness limiting life expectancy (<1 year).
- Severe restrictive lung disease.
- Obstructive lung disease.
- Diffusing capacity of the lung for carbon monoxide <30% predicted.
- Residual volume > or = 120% predicted.
- Documented sustained improvement of patient's IPF condition up to 12 months prior to randomization with or without IPF-specific therapy.
- Recent pulmonary or upper respiratory tract infection (up to 4 weeks prior to randomization).
- Acute or chronic impairment (other than dyspnea) limiting the ability to comply with study requirements.
- Chronic heart failure with New York Heart Association (NYHA) class III/IV or known left ventricular ejection fraction <25%.
- Alanine aminotransferase (ALT/SGPT) and/or aspartate aminotransferase (AST/SGOT) > 1.5 times the upper limit of the normal ranges.
- Moderate to severe hepatic impairment.
- Serum creatinine > or = 2.5 mg/dl or chronic dialysis.
- Hemoglobin concentration <75% the lower limit of the normal ranges.
- Systolic blood pressure <85 mmHg.
- Pregnancy or breast-feeding.
- Current drug or alcohol dependence.
- Chronic treatment with the following drugs prescribed for IPF (within 4 weeks of randomization):oral corticosteroids (>20 mg/day of prednisone or equivalent), immunosuppressive or cytotoxic drugs, antifibrotic drugs, chronic use of N-acetylcysteine (prescribed for IPF).
- Oral anticoagulants other than those indicated for a venous or arterial thrombotic disease.
- Treatment with glibenclamide (glyburide) and calcineurin inhibitors (cyclosporine A, tacrolimus) up to 1 week prior to randomization.
- Treatment with an endothelin receptor antagonist up to 3 months prior to randomization.
- Participation in the BUILD 1 trial.
- Treatment with another investigational drug up to 3 months prior to randomization or planned treatment.
- Known hypersensitivity to bosentan or any of the excipients.
Trial design
Primary purpose
Treatment
Allocation
Randomized
Interventional model
Parallel Assignment
Masking
Quadruple Blind
616 participants in 2 patient groups, including a placebo group
Bosentan
Experimental group
Description:
Subjects receive bosentan 62.5 mg twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg b.i.d (if body weight \> 40 kg) or bosentan 62.5 mg b.i.d. (if body weight \< 40 kg)
Treatment:
Drug: Bosentan
Placebo
Placebo Comparator group
Description:
Subjects receive placebo matching the bosentan treatment regimen
Treatment:
Drug: Placebo
Trial contacts and locations
117
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems